C-Phycocyanin and Phycocyanobilin as a Novel Adjuvant in Hepatitis B Vaccine.

C-藻蓝蛋白和藻蓝胆素作为乙型肝炎疫苗的新型佐剂

阅读:6
作者:Abdali Nargess, Tabaripour Reza, Javadi Solaleh, Nasirikenari Mehrab, Birjandi Mehdi, Siavashi Vahid, Naghavi Mohammad Reza, Hasani Zahra, Ahmari Ali, Hanifi Hossein
BACKGROUND: Vaccine adjuvants are components that enhance immune responses to an antigen. Given the importance of adjuvants, research on novel adjuvants with higher efficacy and fewer adverse effects remains crucial. Spirulina (Arthrospira sp.), an aqueous, photosynthetic, filamentous, spiral, multicellular microalga also classified as a cyanobacterium, is well known for its high protein content, vitamins, essential fatty acids, and amino acids. C-phycocyanin (C-PC) is one of the most significant proteins in Spirulina. OBJECTIVES: This study aimed to investigate the adjuvant capabilities of three Spirulina-derived substances-Spirulina extract, C-phycocyanin (C-PC), and phycocyanobilin (PCB)-in conjunction with the Hepatitis B surface antigen (HBsAg). METHODS: Vaccine groups received the vaccine and adjuvants three times at two-week intervals, administered either orally or by injection in encapsulated or naked forms. To use the injectable form while preventing antigenic effects from the C-PC protein portion, the PCB portion was isolated and used as an injectable adjuvant. RESULTS: The highest levels of interferon gamma (IFN-γ) and interleukin 4 (IL-4) stimulation were observed in the naked PCB form with the vaccine. In both oral and injectable forms of PCB and C-PC, results indicated an increased expression of Hepatitis B surface antibodies (HBsAb) in response to the antigen. The absence of a significant difference between C-PC and Spirulina extract in oral form suggested that the adjuvant effect of this microalga was primarily due to the C-PC compound. Additionally, the injectable form of PCB led to the highest HBsAb expression level. This enhancement of the humoral immune response indicated that these compounds have potential as adjuvants in both oral and injectable forms. CONCLUSIONS: These findings suggest the potential for improved Hepatitis B vaccine efficacy with this novel adjuvant, paving the way for further evaluation with other vaccines.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。